You are here: Industry Insights > AZD1222

News List

AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine americanpharmaceuticalreview
September 07, 2020
Albany Molecular Research, Inc. (AMRI) has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.
PhIII US trial for AZ' coronavirus vaccine pharmatimes
September 02, 2020
AstraZeneca has announced the advance of experimental coronavirus vaccine AZD1222 into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity in the prevention of COVID-19.
Oxford Biomedica enters Covid-19 vaccine manufacturing deal pharmaceutical-technology
September 02, 2020
Oxford Biomedica will reserve capacity for the vaccine candidate in up to three manufacturing suites at its Oxbox facility.
Phase III trials of AstraZeneca COVID-19 vaccine candidate begins in US expresspharma
September 02, 2020
AZD1222 is already undergoing late-stage clinical trials in Britain, Brazil and South Africa, with additional trials planned in Japan and Russia.
Catalent and AstraZeneca Enter Vaccine Manufacturing Deal contractpharma
August 25, 2020
Catalent Inc. will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.
AstraZeneca Concludes Agreement with EC for COVID-19 Vaccine americanpharmaceuticalreview
August 19, 2020
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
EC and UK sign agreements for Covid-19 vaccines supply pharmaceutical-technology
August 18, 2020
The European Commission (EC) and the UK Government have entered into separate agreements for the supply of potential Covid-19 vaccines.
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine worldpharmanews
August 17, 2020
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
AstraZeneca signs first deal to supply Covid-19 vaccine in China pharmaceutical-technology
August 07, 2020
AstraZeneca partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
Emergent BioSolutions Signs Agreement with AstraZeneca contractpharma
August 04, 2020
Emergent BioSolutions Inc. has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

Previous page 1 2 3 4 Next page